The $1.4 billion obesity and diabetes research partnership launched by Bayer and CuraGen has begun to bear fruit, the companies said on Wednesday. The two have chosen 31 small molecule targets in obesity and diabetes and have finished screening against four of those targets. The CuraGen targets are designated as “high priority” for screening at Bayer, the companies said in a statement.
The two companies struck their massive deal in early 2001. CuraGen agreed to provide 80 drug targets for obesity and diabetes in the course of five years. The two jointly agreed to bring 12 drugs to clinical development, sharing both late-stage preclinical and clinical development costs and profits for any resulting drugs. CuraGen is supplying its pharmacogenomic, bioinformatics, and functional genomics knowledge, and Bayer is handling high-throughput screening, combinatorial chemistry, medicinal chemistry, and pharmacology.
If urine microalbumin levels are high, ACE-inhibitors should be considered even if blood pressure is normal.